Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Hetero Healthcare
10 tablet
Gefitinib
Keep in cold place
Delivering To:
Overview
Gefitero 250mg Tablet is an anticancer medicine prescribed for treating lung cancer. Patients who have not received prior cancer treatment, have abnormal epidermal growth factor receptor (EGFR) genes, and whose cancer has progressed to other parts of their body are treated with it. Gefitinib is the active ingredient in Gefitero 250mg Tablet, an antineoplastic medication that belongs to the class of tyrosine kinase inhibitors. Only a trained medical professional should supervise the use of Gefitero 250mg Tablet.
non-small cell lung cancer (NSCLC)
Used to manage adults with non-small cell lung cancer
Gefitero 250mg Tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Diarrhea
Fever
Allergic skin reaction
Nausea and Vomiting
Increase in liver enzyme levels
Eye irritation
Difficulty in breathing
Abdominal pain
Sore throat
Redness around fingernails
Unusual bleeding (in cough and urine), eye irritation or swelling of the ankles or feet
Depending on your health and body tolerance, the doctor will advise you on the dosage strength and frequency. Consume the entire Gefitero 250mg Tablet with water. Avoid cutting or crushing it. In a case of an overdose, seek immediate medical attention and get in touch with your doctor.
Gefitero Tablet is a prescription medication that fights cancer. It functions by preventing the abnormal protein that causes cancer cells to proliferate from doing its job. This is useful in stopping or preventing the growth of cancerous cells. Gefitero Tablet is a derivative of anilinoquinazoline that works with a kinase inhibitor to block the abnormal protein known as the epidermal growth factor receptor (EGFR). This helps in reducing the size of tumors in people with non-small cell lung cancer and slowing or stopping the development of cancer cells.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine. Alcohol use and the Gefitero 250mg Tablet may interact, although this is not certain. Kindly get more guidance from your physician.
Pregnancy
consult your doctor
Do not take Gefitero 250mg Tablet without consulting the doctor, in case of pregnancy. There is clear evidence of a risk to the developing embryo; Gefitero Tablet should not be used during pregnancy. In certain life-threatening situations, however, if the benefits are greater than the possible risks, the doctor might sometimes recommend it. Please speak with your physician.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Because it is unknown whether gefitinib goes into breast milk, you should not breastfeed while taking this medication.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Gefitero 250mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine. It is advised to use the Gefitero 250mg Tablet with caution if you have liver problems. The liver metabolizes this medication, which may have an impact on liver function. Before beginning this drug, it is advisable to speak with your doctor.
If a patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose
Gefitero 250 mg Tablet is an anticancer medicine used for the treatment of cancer of the lungs. Take the medicine under the supervision of a qualified physician. This medicine is not recommended for use in patients with lung and liver diseases.
Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that regulate their growth. This medicine works by binding the chemical messenger, EGFR, thus inhibiting the cancer signaling pathways. This is how the medicine inhibits further growth of the cancer cells.
Side Effects of this medicine include nausea, rash, vomiting, and weight loss. It may cause severe diarrhea, drink plenty of fluids or consult the doctor if it happens. It makes the patient sensitive to sunlight, hence wear protective clothing or use sunscreen while going out.
This tablet is a pill to be administered orally, once a day without food as prescribed by the concerned specialist. Take Gefitinib Tablet empty stomach, at least 1 hour before or 2 hours after meals. Take it at the same time each day so that you remember when to take it
Do not drive if you have any symptoms that affect your ability to concentrate and react. Gefitero Tablet makes you feel weak. This may affect your driving ability.
Even advanced non-small-cell lung cancer (NSCLC) can be treated with Gefitero, a targeted medication therapy.
Gefitero 250mg tablets should not be taken two hours before or one hour after taking an antacid or medication that lowers stomach acid.
Yes, you can take a Gefitero Tablet 10 with or without food. For consistency, it's best to take it at the same time every day.
Yes, this medication may interact with some antifungals and anticoagulants. Before beginning any new drug, always get your doctor's approval.
You can dissolve the tablet in 120–240 mL of plain drinking water and take it right away if swallowing is a problem.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Fukuoka. M., Yano. S., Giaccone. G., Tamura. T. Nakagawa. K., Douillard. J.‑Y., Nishiwaki. Y., Vansteenkiste. J., Kudoh. S., & Mizuuchi. H. (2024). Multi‑institutional randomized Phase II trial of gefitinib (Iressa, ZD1839) for previously treated patients with advanced non‑small‑cell lung cancer (IDEAL‑1). Journal of Clinical Oncology, 22(11), 2231–2239.
Saraswati. E. N., Wulandari. L., Erawati. D., & Febriani. A. (2024). Comparison between the originator and me‑too drugs of first‑generation EGFR‑TKI in EGFR‑mutant NSCLC patients: A retrospective cohort study. International Journal of Research Publications. 147(1), 236–244.
Sim. E. H. A., Yang. I. A., Wood‑Baker. R., Bowman. R. V., & Fong. K. M. (2025). Gefitinib for advanced non‑small cell lung cancer. Cochrane Database of Systematic Reviews. 1(1), https://doi.org/10.1002/14651858.
Wo. H., He. J., Zhao. Y., Yu. H., Chen. F., Yi. H. (2018). The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer, 9(8), 1455-1465.
Xu. J.‑M., Li. Y.‑M., Liu. X.‑Q., Zhang. Y., Han. Y., Yang. W.‑W., & Song. S.‑T. (2024). Clinical observation of gefitinib for the treatment of 125 cases with advanced non‑small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 29(1), 66–69.
Hetero Healthcare
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.